Other relevant news · Page 6 · Mind Medicine Australia
Mind Medicine Australia logo
Donate

Other relevant news

Psychedelics are Exploding in the Startup Community as Founders Say it Makes Them Better Leaders

FortuneWell, October 6, 2022

Ayahuasca’s effects may feel like “talk therapy on steroids” because the hallucinations reveal what many interpret as a deeper truth about themselves, their life, or life in general. Often called ayahuasca “teachings,” these visions may provide the type of self-awareness critical to being a good leader. Business leadership research shows that when leaders can regulate their own negative emotional responses, they can better identify their team’s needs and provide them the encouragement or motivation they need.

Kiwi trial to investigate psilocybin and treatment-resistant depression

NZ Herald, September 28, 2022

A new trial is set to look into whether psilocybin could provide effective treatment for those with severe depression.

Researchers Studying Psychedelic Drug as Treatment for Alzheimer’s Disease

High Times, September 21, 2022

A Toronto-based biotech company is studying a psychedelic drug based on DMT as a treatment for Alzheimer’s disease with a Phase ll clinical trial in Argentina.

Mushrooms for meds: Psychedelics are changing treatment ways in Israel

Y Net News, September 16, 2022

Ecstasy for PTSD and ketamine for long-term depression – is this game changer set to revolutionize mental health treatment in Israel and elsewhere?

Psilocybin Study To Investigate the Serotonin System in Autism

Technology Networks, September 7, 2022

Technology Networks spoke to Tobias Whelan, PhD student at King’s College London and research scientist at COMPASS Pathways, who is conducting the study, to learn more about this first-ever mechanistic study of psilocybin in autistic adults.

Is the Serotonin Hypothesis about Depression Wrong?

Amen Clinics, August 30, 2022

For over 30 years of clinical practice, Amen Clinics has been saying that a serotonin imbalance may be present in some people with depression, but it is not the only cause of depressive symptoms. Depression is not just one thing. Find out the seven causes of depression that aren’t related to serotonin.

Psychedelic Drugs Take On Depression

Nature Briefing, August 24, 2022

Mind-altering drugs might provide relief for those who don’t respond to conventional therapies — but does the hype outweigh the hope? What is clear is that new therapies are urgently needed. The coronavirus pandemic has left more people in mental distress than ever before. Psychedelics offer the possibility of relief for people who have no other options.

Psychedelic Drug Therapy a Breakthrough for Alcohol Dependence?

Medscape, August 24, 2022

Psilocybin paired with psychotherapy is associated with a robust and sustained decrease in drinking among adults with alcohol use disorder (AUD), new research suggests.

The long history of psychedelics in religion, from ergot-spiked wine to magic mushrooms

ABC News, August 21, 2022

In the last century, psychedelics have gone from being at the cutting edge of medical science, to a symbol of the 1960s counterculture, and back again.

The Need For 100,000 Psychedelic Facilitators Is Real

LA Weekly, August 3, 2022

The experts are pretty sure it’s going to take 100,000 psychedelic facilitators for the new industry to provide treatment to the masses.

Canadian patients fighting for psilocybin access sue federal government

National Post, August 2, 2022

‘This is the landmark case that is going to legalize psychedelics in Canada’

Restrictions on Psilocybin ‘Magic Mushrooms’ Are Easing as Research Ramps Up

Scientific American, August 1, 2022

Here’s how the psychedelic substance’s legal status has been shifting.

Biden administration plans for legal psychedelic therapies within two years

The Intercept, July 27, 2022

A letter from the Health and Human Services Department discloses the anticipated FDA approval of MDMA and psilocybin treatments.

Major health insurer opens door to psychedelic drugs

The Australian, July 26, 2022

Health insurer says psychedelics’ medicinal potential is ‘extraordinary’ amid growing evidence MDMA and psilocybin can be used to treat some mental illnesses.

Microdosing: Scientists tackle psychedelic trend becoming ‘creative enhancer of choice’

The Age, July 23, 2022

Microdosing is a different way of consuming psychedelic medicines, which involves regularly taking small amounts of a psychedelic.

Biotech Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs

The Australian, July 21, 2022

In a groundbreaking development, the US FDA has just approved a clinical trial studying the effects of naturally derived psychedelic medicines.

Brains, genes and chemical imbalances – how explanations of mental illness affect stigma

The Conversation, July 20, 2022

For three decades, people have been deluged with information suggesting that depression is caused by a “chemical imbalance” in the brain – namely an imbalance of a brain chemical called serotonin. However, our latest research review shows that the evidence does not support it.

Psychedelics for mental health treatment

ABC Nightlife, July 11, 2022

Writer Michael Pollan discusses how psychedelics are being used now and into the future, to successfully treat people with a range of disorders, addictions and mental illnesses.

Can microdosing psychedelics improve your mental health? Here’s what the science says

ABC News, July 3, 2022

Early results from trials on the therapeutic potential of large doses (macrodosing) of psychedelics have been promising.

Psychedelics Give a Glimpse of Enlightenment

Psychology Today, July 3, 2022

Our brains may be filters that are inhibiting us from experiencing reality.

Subscribe to our newsletter

Stay in touch with Mind Medicine Australia:

×